Name

Vendexta

Alternate Names

Venetoclax

Abbreviations

None

Category

Chemotherapy

Subcategory

BCL2 Inhibitor

NSC Number

None

Primary Site

None

Histology

Lymphoma

Remarks

6/15/2018: FDA has approved, under priority review, Venclexta (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy

Coding

This drug should be coded
Glossary